Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

10 Mar 2017

Abstract excerpt

Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including mixed-lineage leukemia-driven AML, and outperforms standard chemotherapies. In addition to the previously characterized mechanism of action of CX-5461...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Protein Degradation and Inhibitors
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28283481
DOI: 10.1182/blood-2016-05-718171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationPMID 28283481Read ↗

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionSemantic proximity Read ↗

Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia.Semantic proximity Read ↗

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.Semantic proximity Read ↗

Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.Semantic proximity Read ↗

Replication Stress Tolerance in Adult T-Cell LeukemiaSemantic proximity Read ↗

STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in <i>TP53</i> -mutated AMLSemantic proximity Read ↗

Preferential induction of apoptosis for primary human leukemic stem cells.Semantic proximity Read ↗

Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent mannerSemantic proximity Read ↗

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaSemantic proximity Read ↗

Flavopiridol induces<i>BCL-2</i>expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemiaSemantic proximity Read ↗

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.